Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin.

نویسندگان

  • Heather Nace
  • Bennett Lorber
چکیده

tomycin levels of 70% of serum is similar. In this case, however, daptomycin was assayed opportunistically, as the patient required repeat knee aspiration for culture after 2 weeks of therapy. It is probable, therefore, that the concentration of daptomycin in synovial fluid reflects either steady-state concentration or accumulation at the site of infection. The therapeutic daptomycin concentration at the site of infection in synovial fluid associated with clinical improvement when used in combination with sodium fusidate add to the data of daptomycin’s utility in osteoarticular infection. The efficacy of daptomycin in osteoarticular infections should be addressed prospectively in sufficiently powered, randomized, controlled trials.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.

The activities of telavancin and vancomycin were compared in vitro and in the rabbit model of aortic valve endocarditis against a methicillin-resistant Staphylococcus aureus strain, COL, and a vancomycin-intermediate S. aureus (VISA) strain, HIP 5836. Telavancin was bactericidal in time-kill studies at a concentration of 5 microg/ml against both COL and HIP5836. Vancomycin was bacteriostatic at...

متن کامل

Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure.

Sir, We read with great interest the case report by Joson et al. in which they describe the successful treatment of methicillinresistant Staphylococcus aureus (MRSA) mitral valve endocarditis with sequential linezolid and telavancin monotherapy, following daptomycin failure. However, we would like to comment on the antimicrobial course and dosing. This report relates to a case of bacteraemia th...

متن کامل

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)

Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently FDA-approved for the treatment of complicated skin and skin-structure infections. Recently, two randomized cli...

متن کامل

Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.

Emerging infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) isolates are more likely to be associated with treatment failures than infections caused by other types of S. aureus. We present a case of pacemaker lead infective endocarditis caused by a non-daptomycin-susceptible strain of VISA. After 8 weeks of parenteral telavancin therapy, the patient achieved microbiologic...

متن کامل

Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.

Telavancin (TD-6424) was discovered in 2000 and became the first marketed semisynthetic lipoglycopeptide in 2009. This parenteral antibacterial agent has a dual mechanism of action and potent in vitro activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and isolates with reduced vancomycin susceptibility. Pharmacokinetic and pharmacodynamic analyses su...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of antimicrobial chemotherapy

دوره 65 6  شماره 

صفحات  -

تاریخ انتشار 2010